Edap Tms vs Profound Medical
FOCL and PROF side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FOCL and PROF compare
Profound Medical scores higher on the StockData Score (5 against 0 for Edap Tms), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FOCL | PROF |
|---|---|---|
| Size and price | ||
| Share price | $3.53 | $7.85 |
| Change, 1 year | 73.9% | 31.1% |
| Change, 5 years | −34.4% | −35.6% |
| Beta (5Y) | 0.53 | 1.03 |
| Employees | 289 | 162 |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 2 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | – | 65.3% |
| Revenue growth, 5Y average | – | 17.1% |
| EPS growth, 5Y average | – | 2.4% |
| Profitability | ||
| Gross margin | – | 73.9% |
| Operating margin | – | −145% |
| Net margin | – | −138% |
| Return on equity | – | −87.0% |
| Return on invested capital | – | −213% |
| Financial health | ||
| Debt / equity | – | 0.11 |
| Interest coverage | – | −105.8× |
| Current ratio | – | 4.54 |
| Piotroski F-score | – | 3 |
| Ownership | ||
| Held by institutions | 41.5% | 45.2% |
| Held by insiders | 6.4% | 1.6% |
| Insider net buying, 12 months | $593K | – |
| Short interest, % of float | – | 4.4% |
Go deeper
- FOCL stock overview
- FOCL income statement
- FOCL valuation and score
- PROF stock overview
- PROF income statement
- PROF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.